A short peptide derived from the gN helix domain of FGF8b suppresses the growth of human prostate cancer cells

Cancer Letters

Volumn 339, Issue 2, 2013, Pages 226-236

  Li, Tao ^a   Luo, Wu ^a   He, Dan ^a   Wang, Ruixue ^a   Huang, Yadong ^a   Zeng, Xiangfeng ^a   Wang, Wenhui ^a   Chen, Xilei ^a   Gao, Susu ^a   Yu, Yonglin ^a   Li, Xiaokun ^b   Wu, Xiaoping ^a,b  

^a JINAN UNIVERSITY   (China)

^b WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

FGF8b; GN helix; Proliferation; Prostate cancer

Indexed keywords

CYCLIN D1; FIBROBLAST GROWTH FACTOR 8; FIBROBLAST GROWTH FACTOR 8B; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PEPTIDE DERIVATIVE; PROLYLASPARAGINYLPHENYLALANYLTHREONYLGLUTAMINYLHISTIDINYLVALYLARGINYLGLUTAMYLGLUTAMINYLSERYLLEUCYLVALINE; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CONTROLLED STUDY; DNA SYNTHESIS; DOWN REGULATION; ENZYME INHIBITION; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; MALE; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE;

FGF8B; GN HELIX; PROLIFERATION; PROSTATE CANCER;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; AMINO ACID SEQUENCE; CARBOXYLESTERASE; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN D1; FIBROBLAST GROWTH FACTOR 8; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICROTUBULE-ASSOCIATED PROTEINS; MITOGEN-ACTIVATED PROTEIN KINASES; PEPTIDES; PROLIFERATING CELL NUCLEAR ANTIGEN; PROSTATIC NEOPLASMS; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEOMICS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, RETINOIC ACID; REPRODUCIBILITY OF RESULTS; SIGNAL TRANSDUCTION;

EID: 84883825423     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.06.001     Document Type: Article

References (39)

1. Lippman M.E., Dickson R.B. Mechanisms of growth control innormal and malignant breast epithelium. Recent Prog. Horm. Res. 1989, 45:383-435.
2. Ware J.L. Growth factors and their receptors as deter in the proliferation and metastasis of human prostate cancer. Cancer Metastasis Rev. 1993, 12:287-301.
3. Crossley P.H., Minowada G., MacArthur C.A., Martin G.R. Roles for FGF8 in the induction, initiation, and maintenance of chick limb development. Cell 1996, 84:127-136.
4. Lee S.M., Danielian P.S., Fritzsch B., McMahon A.P. Evidence that FGF8 signalling from the midbrain-hindbrain junction regulates growth and polarity in the developing midbrain. Development 1997, 124:959-969.
5. Leung H.Y., Dickson C., Robson C.N., Neal D.E. Over-expression of fibroblast growth factor-8 in human prostate cancer. Oncogene 1996, 12:1833-1835.
6. Gemel J., Gorry M., Ehrlich G.D., MacArthur C.A. Structure and sequence of human FGF8. Genomics 1996, 35:253-257.
7. Tanaka A., Furuya A., Yamasaki M., Hanai N., Kuriki K., Kamiakito T., Kobayashi Y., Yoshida H., Koike M., Fukayama M. High frequency of fibroblast growth factor (FGF) 8 expression in clinical prostate cancers and breast tissues, immunohistochemically demonstrated by a newly established neutralizing monoclonal antibody against FGF 8. Cancer Res. 1998, 58:2053-2056.
8. Dorkin T.J., Robinson M.C., Marsh C., Bjartell A., Neal D.E., Leung H.Y. FGF8 over-expression in prostate cancer is associated with decreased patient survival and persists in androgen independent disease. Oncogene 1999, 18:2755-2761.
9. Valve E.M., Nevalainen M.T., Nurmi M.J., Laato M.K., Martikainen P.M., Härkonen P.L. Increased expression of FGF-8 isoforms and FGF receptors in human premalignant prostatic intraepithelial neoplasia lesions and prostate cancer. Lab. Invest. 2001, 81:815-826.
10. Gnanapragasam V.J., Robinson M.C., Marsh C., Robson C.N., Leung H.Y. FGF8 isoform b expression in human prostate cancer. Br. J. Cancer 2003, 88:1432-1438.
11. Song Z., Wu X., Powell W.C., Cardiff R.D., Cohen M.B., Tin R.T., Matusik R.J., Miller G.J., Roy-Burman P. Fibroblast growth factor 8 isoform b over-expression in prostate epithelium: a new mouse model for prostatic intraepithelial neoplasia. Cancer Res. 2002, 62:5096-5105.
12. Valta M.P., Tuomela J., Vuorikoski H., Loponen N., Vaananen R.M., Pettersson K., Vaananen H.K., Harkonen P.L. FGF-8b induces growth and rich vascularization in an orthotopic PC-3 model of prostate cancer. J. Cell Biochem. 2009, 107:769-784.
13. Song Z., Powell W.C., Kasahara N., van Bokhoven A., Miller G.J., Roy-Burman P. The effect of fibroblast growth factor 8, isoform b, on the biology of prostate carcinoma cells and their interaction with stromal cells. Cancer Res. 2000, 60:6730-6736.
14. Rudra-Ganguly N., Zheng J., Hoang A.T., Roy-Burman P. Down regulation of human FGF8 activity by antisense constructs in murine fibroblastic and human prostatic carcinoma cell systems. Oncogene 1998, 16:1487-1492.
15. Valta M.P., Tuomela J., Bjartell A., Valve E., Väänänen H.K., Härkönen P. FGF-8 is involved in bone metastasis of prostate cancer. Int. J. Cancer 2008, 123:22-31.
16. Schally A.V. Newapproachesto thetherapyof various tumors based on peptide analogues. Horm. Metab. Res. 2008, 40:315-322.
17. Aguzzi M.S., Faraone D., D'Arcangelo D., De Marchis F., Toietta G., Ribatti D., Parazzoli A., Colombo P., Capogrossi M.C., Facchiano A. The FGF-2 derived peptide FREG inhibits melanoma growth in vitro and in vivo. Mol. Ther. 2011, 19:266-273.
18. Wu X., Yan Q., Huang Y., Huang H., Su Z., Xiao J., Zeng Y., Wang Y., Nie C., Yang Y., Li X. Isolation of a novel basic FGF-binding peptide with potent antiangiogenetic activity. J. Cell Mol. Med. 2010, 14:351-356.
19. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 72:248-254.
20. Wang C., Lin S., Nie Y., Jia X., Wang J., Xiao J., Wu J., Li X., Wu X. Mechanism of antitumor effect of a novel bFGF binding peptide on human colon cancer cells. Cancer Sci. 2010, 101:1212-1218.
21. Mattila M.M., Härkönen P.L. Role of fibroblast growth factor 8 in growth and progression of hormonal cancer. Cytokine Growth Factor Rev. 2007, 18:257-266.
22. Blunt A.G., Lawshe A., Cunningham M.L., Seto M.L., Ornitz D.M., MacArthur C.A. Overlapping expression and redundant activation of mesenchymal fibroblast growth factor (FGF) receptors by alternatively spliced FGF-8 ligands. The Journal of Biological Chemistry. 1997, 272:3733-3738.
23. Kwabi-Addo B., Ozen M., Ittmann M. The role of fibroblast growth factors and their receptors in prostate cancer. Endocr. Relat. Cancer 2004, 11:709-724.
24. Valta M.P., Tuomela J., Vuorikoski H., Loponen N., Vaananen R.M., Pettersson K., Vaananen H.K., Harkonen P.L. FGF-8b Induces growth and rich vascularization in an orthotopic PC-3 model of prostate cancer. J. Cell. Biochem. 2009, 107:769-784.
25. Pavletich N.P. Mechanisms of cyclin-dependent kinase regulation:structures of Cdks, their cyclin activators, and Cip and INK4 inhibitors. J. Mol. Biol. 1999, 287:821-828.
26. Agarwal R. Cell signaling and regulators of cell cycle as molecular targets for prostate cancer prevention by dietary agents. Biochem. Pharmacol. 2000, 60:1051-1059.
27. Takuwa N., Takuwa Y. Regulation of cell cycle molecules by the Ras effect or system. Mol. Cell. Endocrinol. 2001, 177:25-33.
28. Nilsson E.M., Brokken L.J., Harkonen P.L. Fibroblast growth factor 8 increases breast cancer cell growth by promoting cell cycle progression and by protecting against cell death. Exp. Cell Res. 2010, 316:800-812.
29. Bartek J., Bartkova J., Lukas J. The retinoblastoma protein pathway in cell cycle control and cancer. Exp. Cell Res. 1997, 237:1-6.
30. Harbour J.W., Luo R.X., Dei Santi A., Postigo A.A., Dean D.C. Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1. Cell 1999, 98:859-869.
31. Jaskulski D., deRiel J.K., Mercer W.E., Calabretta B., Baserga R. Inhibition of cellular proliferation by antisense oligodeoxynucleotides to PCNA cyclin. Science 1988, 240:1544-1546.
32. Napoli J.L. Interactions of retinoid binding proteins and enzymes in retinoid metabolism. Biochim. Biophys. Acta 1999, 1440:139-162.
33. Delva L., Bastie J.N., Rochette-Egly C., Kraiba R., Balitrand N., Despouy G., Chambon P., Chomienne C. Physical and functional interactions between cellular retinoic acid binding protein II and the retinoic acid-dependent nuclear complex. Mol. Cell. Biol. 1999, 19:7158-7167.
34. Despouy G., Bastie J.N., Deshaies S., Balitrand N., Mazharian A., Rochette-Egly C., Chomienne C., Delva L. CyclinD3 is a cofactor of retinoic acid receptors, modulating their activity in the presence of cellular retinoic acid-binding protein II. J. Biol. Chem. 2003, 278:6355-6362.
35. Venable M.E., Zimmerman G.A., McIntyre T.M., Prescott S.M. Platelet-activating factor: a phospholipid autacoid with diverse actions. J. Lipid Res. 1993, 34:691-702.
36. Tjoelker L.W., Wilder C., Eberhardt C., Stafforini D.M., Dietsch G., Schimpf B., Hooper S., Le Trong H., Cousens L.S., Zimmerman G.A., Yamada Y., McIntyre T.M., Prescott S.M., Gray P.W. Anti-inflammatory properties of a platelet-activating factor acetylhydrolase. Nature 1995, 374:549-553.
37. Ho Y.S., Swenson L., Derewenda U., Serre L., Wei Y., Dauter Z., Hattori M., Adachi T., Aoki J., Arai H., Inoue K., Derewenda Z.S. Brain acetylhydrolase that inactivates platelet-activating factor is a G-protein-like trimer. Nature 1997, 385:89-93.
38. Manya H., Aoki J., Kato H., Ishii J., Hino S., Arai H., Inoue K. Biochemical characterization of various catalytic complexes of the brain platelet-activating factor acetylhydrolase. J. Biol. Chem. 1999, 274:31827-31832.
39. Langman M.J., Cheng K.K., Gilman E.A., Lancashire R.J. Effect of anti-inflammatory drugs on overall risk of common cancer: case-control study in general practice research database. BMJ 2000, 320:1642-1646.